Emerging new Company veriNOS pharmaceuticals, established in October 2022, Led by CEO, Christian Wandersee and CMO Professor John Stover, provides an update on its revival of late-stage drug candidate ronopterin for the treatment of Traumatic Brain Injury (TBI). Ronopterin is the first and only iNOS inhibitor which has demonstrated repeated signs of neuroprotection in TBI […]
Science of small things does not sound like something that can have a big impact on the world, but nanotechnology has proved this is wrong. Tissue engineering, efficient drug delivery and more sensitive screening for diseases are just a few examples. According to Professor Molly Stevens, the new technologies can democratise access to healthcare. She […]
14 February 2023 – Optimum Strategic Communications (“Optimum”), the specialist life sciences communications consultancy, today announces that it has hired Jonathan Edwards and Hana Malik, two highly experienced investor relations and communications professionals, to join as permanent members of its team. Edwards and Malik have joined Optimum as Account Directors and will be advising clients across […]
… And just like that it’s ANOTHER new year! If you are still gathering your thoughts on how best to maximise your time in 2023, allow us to flag some of the most impactful and innovative conferences in Life Sciences. The Optimum team really enjoyed being back in person for the majority of the conferences […]
In this report, Amy Brown, Edwin Elmhirst and Joanne Fagg of Evaluate Vantage discuss the outlook for biopharma in 2023. According to the team, there is hope for an improvement in 2023 after the trials of the last two years, although few are expecting a dramatic recovery. Check out the Evaluate team’s thoughts on the […]